News
SYRE
104.00
+1.06%
1.09
Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Roivant Sciences (ROIV) and Cogent Biosciences (COGT)
TipRanks · 22h ago
Should Wider Losses Require Action From Spyre Therapeutics (SYRE) Investors?
Simply Wall St · 1d ago
XBI, SYRE, EXEL, BIIB: ETF Outflow Alert
NASDAQ · 1d ago
Following Earnings Losses, Is Spyre Therapeutics (SYRE) Still Worth Its 11x P/B?
Simply Wall St · 3d ago
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
Benzinga · 4d ago
Weekly Report: what happened at SYRE last week (1102-1106)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Spyre Therapeutics (SYRE) and Alnylam Pharma (ALNY)
TipRanks · 11/05 11:10
Spyre Therapeutics Faces Ongoing Dilution Risk and Strategic Constraints From Heavy Reliance on External Financing
TipRanks · 11/05 06:00
How Investors May Respond To Spyre Therapeutics Stock After Phase 2 Data And Wider Losses
Simply Wall St · 11/05 03:43
Spyre Therapeutics: IBD Potential and IL-23 Programs Support Unchanged $130 Price Target Despite Rheumatology Setbacks
TipRanks · 11/04 21:05
Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Waters (WAT) and Tarsus Pharmaceuticals (TARS)
TipRanks · 11/04 21:00
Spyre Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 11/04 15:34
Spyre Therapeutics Price Target Raised to $135.00/Share From $130.00 by Guggenheim
Dow Jones · 11/04 15:34
Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $135
Benzinga · 11/04 15:23
Spyre Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 11/04 14:35
Spyre Therapeutics Price Target Cut to $120.00/Share From $123.00 by Wedbush
Dow Jones · 11/04 14:35
Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120
Benzinga · 11/04 14:25
Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 11/04 13:02
Spyre Therapeutics price target lowered to $120 from $123 at Wedbush
TipRanks · 11/04 12:55
Spyre Therapeutics price target raised to $131 from $123 at Stifel
TipRanks · 11/04 11:52
More
Webull provides a variety of real-time SYRE stock news. You can receive the latest news about Spyre Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About SYRE
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).